BioRx receives limited distribution rights from Baxter for AATD drug GLASSIA

BioRx, a specialty pharmacy company, has received limited distribution rights from Baxter International Inc. for a new drug, GLASSIA™ [Alpha 1-Proteinase Inhibitor (Human)], the first and only liquid, ready-to-use treatment for alpha-1 antitrypsin deficiency (AATD) in the United States. AATD is a genetic disorder that causes low levels of alpha 1-antitrypsin, resulting in emphysema. AATD is also referred to as "genetic" or "congenital" emphysema.

“Our agreement with Kamada broadens the therapeutic options available to alpha-1 patients and their treating physicians. Likewise, the addition of BioRx to our distribution channel extends the high-quality homecare choices available to the growing population of diagnosed alpha-1 patients.”

As a result of this limited distribution agreement, BioRx will also be added as a distributor of ARALAST NP, a similar product to Baxter's first alpha-1 proteinase inhibitor (A1-Pi), ARALAST, originally launched in 2003. BioRx will begin stocking both GLASSIA and ARALAST NP this month.

On August 24, Baxter announced an agreement with Kamada LTD, the company that manufactures GLASSIA, for exclusive commercial rights to GLASSIA in the United States, Australia, New Zealand and Canada. The FDA approved GLASSIA, which is indicated for chronic augmentation and maintenance therapy in individuals with emphysema due to congenital deficiency of A1-PI, on July 1, 2010. For more about Baxter and GLASSIA, visit: http://www.baxter.com/press_room/press_releases/2010/08_24_10_glassia.html

"We congratulate Baxter on its acquisition of GLASSIA, said Eric Hill, vice president of BioRx. "BioRx is pleased to offer alpha-1 patients a unique formulation of alpha-1 proteinase inhibitor that may ease their therapy routine. Moreover, we are proud to enter the alpha-1 marketplace and be able to offer our commitment and support to the alpha-1 community."

Larry Guiheen, president of Global BioPharmaceuticals for Baxter BioScience, said "Our agreement with Kamada broadens the therapeutic options available to alpha-1 patients and their treating physicians. Likewise, the addition of BioRx to our distribution channel extends the high-quality homecare choices available to the growing population of diagnosed alpha-1 patients."

Source:

 BioRx

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Baxter International Inc.. (2019, June 20). BioRx receives limited distribution rights from Baxter for AATD drug GLASSIA. News-Medical. Retrieved on May 17, 2022 from https://www.news-medical.net/news/20101013/BioRx-receives-limited-distribution-rights-from-Baxter-for-AATD-drug-GLASSIA.aspx.

  • MLA

    Baxter International Inc.. "BioRx receives limited distribution rights from Baxter for AATD drug GLASSIA". News-Medical. 17 May 2022. <https://www.news-medical.net/news/20101013/BioRx-receives-limited-distribution-rights-from-Baxter-for-AATD-drug-GLASSIA.aspx>.

  • Chicago

    Baxter International Inc.. "BioRx receives limited distribution rights from Baxter for AATD drug GLASSIA". News-Medical. https://www.news-medical.net/news/20101013/BioRx-receives-limited-distribution-rights-from-Baxter-for-AATD-drug-GLASSIA.aspx. (accessed May 17, 2022).

  • Harvard

    Baxter International Inc.. 2019. BioRx receives limited distribution rights from Baxter for AATD drug GLASSIA. News-Medical, viewed 17 May 2022, https://www.news-medical.net/news/20101013/BioRx-receives-limited-distribution-rights-from-Baxter-for-AATD-drug-GLASSIA.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer